We are live on
!
Find out more
PCM
Perkins Capital Management Portfolio holdings
AUM
$133M
Turnover
16.67%
1-Year Est. Return
127.86%
This Fund
S&P 500
This Quarter
Est. Return
+20.91%
1 Year Est. Return
+127.86%
3 Year Est. Return
+303.11%
5 Year Est. Return
+333.48%
10 Year Est. Return
–
AUM
$173M
AUM Growth
+$20M
(+13%)
Cap. Flow
-$415K
Cap. Flow
% of AUM
-0.24%
Top 10 Holdings %
Top 10 Hldgs %
35.73%
Holding
114
New
14
Increased
30
Reduced
33
Closed
8
Avg Time Held
3
years
Top 10 Avg Time Held
2.1
years
Top 20 Avg Time Held
2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Streamline Health Solutions
STRM
|
+$2.62M |
| 2 |
Digi International
DGII
|
+$2.23M |
| 3 |
CEMI
Chembio diagnostics, Inc.
CEMI
|
+$1.61M |
| 4 |
RYTHM Inc
RYM
|
+$1.57M |
| 5 |
ZIXI
Zix Corporation
ZIXI
|
+$1.51M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Magnite
MGNI
|
+$7.28M |
| 2 |
Vericel Corp
VCEL
|
+$4.43M |
| 3 |
BioTelemetry, Inc.
BEAT
|
+$2.35M |
| 4 |
SOLO
Electrameccanica Vehicles Corp. Ltd.
SOLO
|
+$2.21M |
| 5 |
Inuvo
INUV
|
+$2.03M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 66% |
| 2 | Technology | 17.34% |
| 3 | Communication Services | 5.94% |
| 4 | Industrials | 4.11% |
| 5 | Consumer Staples | 2.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Vericel Corp
VCEL
$2.1B
| $8.62M | 4.98% |
155,107
-97,930
| -39% | -$4.43M |
2014 Q3
26 quarters
|
|
2
NeoGenomics
NEO
$2.22B
| $7.75M | 4.48% |
160,800
-20,450
| -11% | -$1.06M |
2013 Q2
31 quarters
|
|
3
CareDx
CDNA
$3.45B
| $7.23M | 4.18% |
106,142
-1,650
| -2% | -$128K |
2017 Q3
14 quarters
|
|
4
Veracyte
VCYT
$3.57B
| $6.8M | 3.93% |
126,480
-600
| -0.5% | -$34.6K |
2018 Q1
12 quarters
|
|
5
Natera
NTRA
$58.3B
| $6.49M | 3.75% |
63,950
-2,100
| -3% | -$230K |
2018 Q2
11 quarters
|
|
6
OptimizeRx
OPRX
$167M
| $5.93M | 3.43% |
121,706
-34,982
| -22% | -$1.69M |
2018 Q2
11 quarters
|
|
7
Axogen
AXGN
$2.09B
| $5.62M | 3.25% |
277,490
| – | – |
2013 Q3
30 quarters
|
|
8
Idexx Laboratories
IDXX
$43.1B
| $5.43M | 3.14% |
11,105
| – | – |
2013 Q3
30 quarters
|
|
|
9
DELISTED
Streamline Health Solutions
STRM
| $4.06M | 2.35% |
131,903
+91,513
| +227% | +$2.62M |
2018 Q2
11 quarters
|
|
|
10
Inuvo
INUV
$7.58M
| $3.86M | 2.23% |
378,261
-167,523
| -31% | -$2.03M |
2018 Q2
11 quarters
|
|
11
Microsoft
MSFT
$4.01T
| $3.65M | 2.11% |
15,493
| – | – |
2014 Q1
28 quarters
|
|
12
DELISTED
FlexShopper
FPAY
| $3.63M | 2.1% |
1,379,370
+73,840
| +6% | +$223K |
2018 Q3
10 quarters
|
|
13
Exagen
XGN
$207M
| $3.56M | 2.06% |
203,530
+71,175
| +54% | +$1.27M |
2019 Q3
6 quarters
|
|
14
Abbott
ABT
$181B
| $3.31M | 1.91% |
27,580
| – | – |
2014 Q1
28 quarters
|
|
15
Rockwell Medical
RMTI
$32.2M
| $3.29M | 1.9% |
25,802
+3,462
| +15% | +$512K |
2013 Q2
31 quarters
|
|
16
DELISTED
Cantaloupe
CTLP
| $3.27M | 1.89% |
279,225
+24,900
| +10% | +$263K |
2020 Q4
1 quarter
|
|
17
Alphatec Holdings
ATEC
$1.69B
| $2.9M | 1.68% |
183,750
| – | – |
2019 Q3
6 quarters
|
|
18
LeMaitre Vascular
LMAT
$1.9B
| $2.62M | 1.52% |
53,750
-850
| -2% | -$39.8K |
2017 Q1
16 quarters
|
|
19
DELISTED
Avinger, Inc. Common Stock
AVGR
| $2.61M | 1.51% |
5,770
-2,021
| -26% | -$970K |
2018 Q4
9 quarters
|
|
20
Eli Lilly
LLY
$1.12T
| $2.56M | 1.48% |
13,708
| – | – |
2013 Q2
31 quarters
|
|
21
AtriCure
ATRC
$2.94B
| $2.51M | 1.45% |
38,350
-2,750
| -7% | -$169K |
2013 Q2
31 quarters
|
|
22
Standard BioTools
LAB
$258M
| $2.44M | 1.41% |
540,825
+172,425
| +47% | +$947K |
2017 Q4
13 quarters
|
|
|
23
Digi International
DGII
$2.72B
| $2.44M | 1.41% |
128,300
+107,500
| +517% | +$2.23M |
2020 Q1
4 quarters
|
|
|
QUMU
24
DELISTED
Qumu Corp.
QUMU
| $2.38M | 1.37% |
351,310
+115,450
| +49% | +$960K |
2019 Q4
5 quarters
|
|
25
DELISTED
Akoustis Technologies Inc
AKTS
| $2.31M | 1.34% |
173,450
-30,750
| -15% | -$447K |
2018 Q4
9 quarters
|
|
Similar funds
AA
WA
AC
BCVI
HAP
RHIG
CWM
SI
Perkins Capital Management's Q1 2021 Portfolio in Review
As of Q1 2021, Perkins Capital Management held 114 positions worth $173M, up 13% from $153M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Perkins Capital Management's Q1 2021 filing shows 14 new, 30 increased, 33 reduced and 8 closed positions. Its largest new stake was Chembio diagnostics, Inc.: 289,680 shares worth $1.02M. The largest sale was Magnite, an estimated $7.28M.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 67% a quarter earlier, followed by Technology and Communication Services.
- Perkins Capital Management's largest Q1 2021 buy was Chembio diagnostics, Inc.: 289,680 shares worth $1.02M.
- Perkins Capital Management added most to Streamline Health Solutions in Q1 2021, an estimated $2.62M increase.
- Perkins Capital Management's biggest Q1 2021 reduction was Magnite, cutting an estimated $7.28M.
- Perkins Capital Management fully exited BioTelemetry, Inc. in Q1 2021, selling an estimated $2.35M.
- Perkins Capital Management's ten largest holdings make up 36% of its $173M portfolio in Q1 2021.
- Perkins Capital Management opened 14 new positions and closed 8 in Q1 2021.
- Perkins Capital Management's portfolio value rose 13% quarter-over-quarter to $173M.
Based on Perkins Capital Management's 13F filing for Q1 2021, filed 28 Apr 2021.